Jeremy Bender - 17 Jan 2023 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Chief Executive Officer, Director
Signature
/s/ Charles N. York II, as Attorney-in-Fact
Issuer symbol
DAWN
Transactions as of
17 Jan 2023
Transactions value $
$0
Form type
4
Filing time
19 Jan 2023, 15:52:50 UTC
Previous filing
13 Feb 2023
Next filing
24 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Stock Option (right to buy Common Stock) Award $0 +244,000 $0.000000 244,000 17 Jan 2023 Common Stock 244,000 $20.87 Direct F1
transaction DAWN Restricted Stock Units Award $0 +76,000 $0.000000 76,000 17 Jan 2023 Common Stock 76,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F3 The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.